Renal tubular injury associated with anagrelide use

Nephrology Dialysis Transplantation

Volumn 20, Issue 5, 2005, Pages 988-990

  Rodwell, Graham E J ^a   Troxell, Megan L ^a   Lafayette, Richard A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute renal failure; Acute tubular necrosis; Side effects

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; AZATHIOPRINE; CYANOCOBALAMIN; HYDROXYUREA; IRON DERIVATIVE; MESALAZINE; MULTIVITAMIN; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; CROHN DISEASE; DRUG USE; ECHOGRAPHY; HUMAN; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LYMPHOCYTIC INFILTRATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIODIC ACID SCHIFF STAIN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; THROMBOCYTE COUNT; THROMBOCYTOSIS;

HUMANS; KIDNEY TUBULES; MALE; MIDDLE AGED; NECROSIS; QUINAZOLINES;

EID: 18944402248     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh726     Document Type: Article

References (5)

1. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002; 99: 1602-1609
2. Anagrelide Study Group. Anagrelide, a therapy for thrombocythermic states: experience in 577 patients. Anagrelide Study Group. Am J Med 1992; 92: 69-76
3. Schafer AI. Thrombocytosis. N Engl J Med 2004; 350: 1211-1219
4. Birgegard G, Bjorkholm M, Kutti J et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004; 89: 520-527
5. Roberts Pharmaceutical Corporation. Agrylin (anagrelide) package insert. Roberts Pharmaceutical Corp., Eatontown, NJ: 1999